Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Forest Laboratories and Cypress Bioscience have announced that Savella, a selective serotonin and norepinephrine dual reuptake inhibitor, was approved by the FDA for the management of fibromyalgia.
Subscribe to our email newsletter
The safety and efficacy of Savella was established in two US pivotal Phase III clinical trials involving over 2,000 patients with fibromyalgia.
The studies showed that Savella doses of 100mg/day and 200mg/day demonstrated statistically significant and clinically meaningful concurrent improvements in pain, patient global assessment and physical function. The companies expect Savella to be available in pharmacies by March 2009.
Howard Solomon, chairman and CEO of Forest Laboratories, said: “We and our partner Cypress Bioscience are very pleased to receive marketing approval for Savella, following a first-cycle review, from the FDA. Savella is a valuable new treatment for patients afflicted with fibromyalgia. Its effectiveness was evaluated based upon the multiple symptoms included in the responder analysis.”